Renal	B-O
cell	I-LF
carcinoma	I-LF
.	B-O
We	B-O
found	B-O
that	B-O
the	B-O
lovastatin-treated	B-O
group	B-O
had	B-O
a	B-O
significantly	B-O
lower	B-O
serum	B-O
level	B-O
of	B-O
cholesterol	B-O
but	B-O
greater	B-O
tumor	B-O
size	B-O
compared	B-O
to	B-O
the	B-O
control	B-O
group	B-O
.	B-O
Tumors	B-O
in	B-O
the	B-O
lovastatin-treated	B-O
group	B-O
also	B-O
weighed	B-O
more	B-O
than	B-O
those	B-O
in	B-O
the	B-O
control	B-O
group	B-O
at	B-O
necropsy	B-O
.	B-O
By	B-O
examining	B-O
the	B-O
resected	B-O
tumor	B-O
tissue,	B-O
we	B-O
found	B-O
that	B-O
the	B-O
lactate	B-O
content	B-O
in	B-O
the	B-O
tumor	B-O
tissue	B-O
of	B-O
the	B-O
lovastatin-treated	B-O
group	B-O
was	B-O
significantly	B-O
higher	B-O
by	B-O
25%	B-O
±	B-O
8.1%	B-O
;	B-O
the	B-O
levels	B-O
of	B-O
VEGF	B-AC
and	B-O
glutathione	[{'token': 'glutathione', 'label': 'B-LF'}]
.	B-O
Moreover,	B-O
tumor	B-O
neovascularization	B-O
testing	B-O
and	B-O
CD31	B-O
staining	B-O
indicated	B-O
that	B-O
the	B-O
angiogenic	B-O
response	B-O
in	B-O
the	B-O
lovastatin	B-O
treatment	B-O
group	B-O
was	B-O
significantly	B-O
stronger	B-O
than	B-O
that	B-O
in	B-O
the	B-O
saline	B-O
group.	B-O
These	B-O
results	B-O
suggested	B-O
that	B-O
treatment	B-O
with	B-O
HMGCR	B-AC
inhibitors	B-O
had	B-O
made	B-O
the	B-O
microenvironment	B-O
of	B-O
the	B-O
tumor	B-O
more	B-O
conducive	B-O
to	B-O
growth.	B-O
It	B-O
has	B-O
been	B-O
established	B-O
that	B-O
elevated	B-O
lactate	B-O
levels	B-O
in	B-O
tumors	B-O
often	B-O
precede	B-O
increased	B-O
levels	B-O
of	B-O
glycolysis	B-O
in	B-O
tumor	B-O
cells.	B-O
Glycolysis	B-O
provides	B-O
energy	B-O
and	B-O
materials	B-O
for	B-O
the	B-O
rapid	B-O
proliferation	B-O
of	B-O
tumor	B-O
cells	B-O
and	B-O
creates	B-O
an	B-O
acidic	B-O
and	B-O
inflammatory	B-O
TME,	B-O
thereby	B-O
promoting	B-O
tumor	B-O
growth	B-O
and	B-O
angiogenesis.	B-O
Moreover,	B-O
the	B-O
accelerated	B-O
growth	B-O
of	B-O
tumors	B-O
promoted	B-O
acidification	I-LF
and	B-O
hypoxia	B-O
in	B-O
the	B-O
TME.	B-O
Based	B-O
on	B-O
this	B-O
inference,	B-O
we	B-O
preliminary	B-O
hypothesized	B-O
that	B-O
HMGCR	B-AC
inhibition	B-O
promoted	B-O
tumor	B-O
growth	B-O
by	B-O
increasing	B-O
glycolysis.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
1.	B-O
Inhibition	B-O
of	B-O
HMGCR	B-AC
promoted	B-O
RCC	B-AC
tumor	B-O
growth.	B-O
.	B-O
This	B-O
finding	B-O
was	B-O
corroborated	B-O
by	B-O
the	B-O
treatment	B-O
of	B-O
ACHN	B-O
and	B-O
786-O	B-O
cells	B-O
with	B-O
other	B-O
statins	B-O
at	B-O
doses	B-O
of	B-O
1	B-O
μM;	B-O
this	B-O
also	B-O
caused	B-O
negligible	B-O
effects	B-O
on	B-O
cell	I-LF
proliferation	B-O
.	B-O
The	B-O
results	B-O
of	B-O
this	B-O
assay	B-O
implied	B-O
that	B-O
HMGCR	B-AC
inhibition	B-O
did	B-O
not	B-O
correlate	B-O
with	B-O
tumor	B-O
growth	B-O
via	B-O
an	B-O
effect	B-O
on	B-O
cell	I-LF
proliferation.	B-O
Next,	B-O
we	B-O
measured	B-O
lactate	B-O
produced	B-O
by	B-O
ACHN	B-O
and	B-O
786-O	B-O
cell	I-LF
lines	B-O
after	B-O
lovastatin	B-O
stimulation.	B-O
At	B-O
the	B-O
indicated	B-O
concentrations,	B-O
lovastatin	B-O
augmented	B-O
the	B-O
release	B-O
of	B-O
lactate	B-O
into	B-O
the	B-O
culture	B-O
medium	B-O
in	B-O
ACHN	B-O
cells	B-O
by	B-O
24%	B-O
to	B-O
69%	B-O
and	B-O
in	B-O
786-O	B-O
cells	B-O
by	B-O
22%	B-O
to	B-O
55%	B-O
.	B-O
To	B-O
confirm	B-O
the	B-O
specificity	B-O
of	B-O
lactate	B-O
production	B-O
enhanced	B-O
by	B-O
lovastatin-inhibited	B-O
HMGCR,	B-O
we	B-O
established	B-O
ACHN	B-O
and	B-O
786-O	B-O
cells	B-O
stably	B-O
expressing	B-O
short	B-LF
hairpin	I-LF
RNA	I-LF
.	B-O
Consistent	B-O
with	B-O
the	B-O
previous	B-O
results,	B-O
the	B-O
extracellular	B-LF
and	B-O
intracellular	B-O
levels	B-O
of	B-O
lactate	B-O
both	B-O
showed	B-O
elevation	B-O
in	B-O
HMGCR	B-AC
knockdown	B-O
cells	B-O
.	B-O
The	B-O
extracellular	B-LF
acidification	I-LF
rate	I-LF
.	B-O
Furthermore,	B-O
supplementation	B-O
with	B-O
MVA,	B-O
a	B-O
downstream	B-O
product	B-O
of	B-O
HMGCR,	B-O
restored	B-O
lovastatin-induced	B-O
lactate	B-O
alterations	B-O
in	B-O
ACHN	B-O
cells	B-O
.	B-O
In	B-O
addition,	B-O
increased	B-O
lactate	B-O
production	B-O
was	B-O
accompanied	B-O
by	B-O
increased	B-O
consumption	B-O
of	B-O
glucose.	B-O
This	B-O
was	B-O
confirmed	B-O
by	B-O
the	B-O
direct	B-O
measurement	B-O
of	B-O
residual	B-O
glucose	B-O
in	B-O
the	B-O
culture	B-O
medium	B-O
and	B-O
flow	B-O
cytometry	B-O
analysis	B-O
by	B-O
the	B-O
fluorescent	B-O
deoxyglucose	B-O
analog	B-O
2-NBDG	B-O
.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
2.	B-O
HMGCR	B-AC
inhibition	B-O
enhanced	B-O
RCC	B-AC
cells	B-O
glycolytic.	B-O
in	B-O
ACHN	B-O
cells.	B-O
Indeed,	B-O
we	B-O
found	B-O
an	B-O
abnormal	B-O
increase	B-O
in	B-O
the	B-O
levels	B-O
of	B-O
PKM2	B-AC
protein	B-O
in	B-O
the	B-O
tumor	B-O
tissue	B-O
of	B-O
lovastatin-treated	B-O
mice	B-O
.	B-O
The	B-O
expression	B-O
of	B-O
PKM2	B-AC
on	B-O
the	B-O
tumor	B-O
cells	B-O
of	B-O
our	B-O
in	B-O
vitro	B-O
culture	B-O
model	B-O
increased	B-O
in	B-O
response	B-O
to	B-O
lovastatin	B-O
treatment;	B-O
this	B-O
occurred	B-O
in	B-O
both	B-O
a	B-O
dose-	B-O
and	B-O
time-dependent	B-O
manner	B-O
.	B-O
These	B-O
results	B-O
were	B-O
also	B-O
reproduced	B-O
upon	B-O
treatment	B-O
with	B-O
other	B-O
statins	B-O
.	B-O
Furthermore,	B-O
existing	B-O
reports	B-O
prove	B-O
that	B-O
PKM2	B-AC
not	B-O
only	B-O
acts	B-O
as	B-O
a	B-O
rate-limiting	B-O
enzyme	B-O
to	B-O
control	B-O
the	B-O
rate	I-LF
of	B-O
glycolysis	B-O
in	B-O
tumor	B-O
cells;	B-O
it	B-O
also	B-O
regulates	B-O
the	B-O
secretion	B-O
of	B-O
VEGF	B-AC
and	B-O
promotes	B-O
tumor	B-O
angiogenesis	B-O
.	B-O
Therefore,	B-O
we	B-O
turned	B-O
our	B-O
attention	B-O
to	B-O
PKM2.	B-O
The	B-O
specificity	B-O
of	B-O
the	B-O
PKM2	B-AC
regulation	B-O
following	B-O
the	B-O
inhibition	B-O
of	B-O
HMGCR	B-AC
by	B-O
statins	B-O
was	B-O
confirmed	B-O
by	B-O
both	B-O
HMGCR	B-AC
knockdown	B-O
and	B-O
MVA	B-AC
supplementation	B-O
experiments	B-O
in	B-O
ACHN	B-O
cells	B-O
.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
3.	B-O
HMGCR	B-AC
inhibition	B-O
enhanced	B-O
PKM2	B-AC
stability.	B-O
.	B-O
We	B-O
found	B-O
that	B-O
a	B-O
reduction	B-O
in	B-O
the	B-O
expression	B-O
of	B-O
PKM2	B-AC
protein	B-O
level	B-O
resulted	B-O
in	B-O
a	B-O
decline	B-O
in	B-O
lactate	B-O
production	B-O
and	B-O
glucose	B-O
consumption;	B-O
this	B-O
effect	B-O
could	B-O
not	B-O
be	B-O
reversed	B-O
by	B-O
the	B-O
further	B-O
application	B-O
of	B-O
lovastatin	B-O
.	B-O
In	B-O
contrast,	B-O
the	B-O
exogenous	B-O
expression	B-O
of	B-O
PKM2	B-AC
significantly	B-O
increased	B-O
lactate	B-O
production	B-O
and	B-O
glucose	B-O
consumption	B-O
in	B-O
ACHN	B-O
cells	B-O
.	B-O
In	B-O
addition,	B-O
the	B-O
level	B-O
of	B-O
VEGF	B-AC
was	B-O
also	B-O
augmented	B-O
with	B-O
the	B-O
exogenous	B-O
expression	B-O
of	B-O
PKM2	B-AC
;	B-O
this	B-O
was	B-O
consistent	B-O
with	B-O
our	B-O
findings	B-O
from	B-O
the	B-O
animal	B-O
model.	B-O
To	B-O
understand	B-O
the	B-O
mechanisms	B-O
underlying	B-O
the	B-O
HMGCR	B-AC
inhibition-induced	B-O
PKM2	B-AC
up-regulation,	B-O
we	B-O
first	B-O
measured	B-O
the	B-O
mRNA	B-O
levels	B-O
of	B-O
PKM2	B-AC
in	B-O
ACHN	B-O
cells.	B-O
There	B-O
was	B-O
no	B-O
significant	B-O
change	B-O
either	B-O
with	B-O
lovastatin	B-O
treatment	B-O
or	B-O
with	B-O
HMGCR	B-AC
knockdown	B-O
.	B-O
This	B-O
suggested	B-O
that	B-O
the	B-O
inhibition	B-O
of	B-O
HMGCR	B-AC
might	B-O
affect	B-O
the	B-O
stability	B-O
of	B-O
the	B-O
PKM2	B-AC
protein.	B-O
Furthermore,	B-O
the	B-O
enzymic	B-O
activity	B-O
of	B-O
PKM2	B-AC
was	B-O
inversely	B-O
related	B-O
to	B-O
the	B-O
regulation	B-O
of	B-O
HMGCR	B-AC
.	B-O
Cycloheximide	B-O
.	B-O
Moreover,	B-O
a	B-O
proteasome	B-O
inhibitor	B-O
.	B-O
These	B-O
data	B-O
revealed	B-O
that	B-O
HMGCR	B-AC
inhibition	B-O
increased	B-O
the	B-O
levels	B-O
of	B-O
PKM2	B-AC
protein	B-O
by	B-O
slowing	B-O
down	B-O
degradation	B-O
by	B-O
the	B-O
proteasome	B-O
and	B-O
by	B-O
promoting	B-O
the	B-O
stability	B-O
of	B-O
PKM2.	B-O
HSP90	B-AC
is	B-O
a	B-O
critical	B-O
regulator	B-O
of	B-O
PKM2	B-AC
protein	B-O
augmentation	B-O
Heat	B-O
shock	I-LF
protein	B-O
90	B-O
.	B-O
Then,	B-O
we	B-O
attenuated	B-O
the	B-O
expression	B-O
of	B-O
HSP90	B-AC
protein	B-O
using	B-O
sh	B-O
RNA	I-LF
and	B-O
found	B-O
that	B-O
the	B-O
effect	B-O
of	B-O
lovastatin	B-O
on	B-O
increasing	B-O
PKM2	B-AC
had	B-O
been	B-O
eliminated	B-O
.	B-O
Moreover,	B-O
HSP90	B-AC
knockdown	B-O
directly	B-O
reduced	B-O
levels	B-O
of	B-O
PKM2	B-AC
.	B-O
These	B-O
findings	B-O
suggested	B-O
that	B-O
the	B-O
inhibition	B-O
of	B-O
HMGCR	B-AC
might	B-O
regulate	B-O
PKM2	B-AC
via	B-O
HSP90.	B-O
To	B-O
verify	B-O
this	B-O
observation,	B-O
we	B-O
performed	B-O
co-immunoprecipitation	[{'token': 'co-immunoprecipitation', 'label': 'B-LF'}]
.	B-O
Notably,	B-O
the	B-O
knockdown	B-O
of	B-O
HSP90	B-AC
by	B-O
sh	B-O
RNA	I-LF
restored	B-O
the	B-O
enhanced	B-O
PKM2	B-AC
enzyme	B-O
activity	B-O
and	B-O
lactate	B-O
production	B-O
caused	B-O
by	B-O
lovastatin	B-O
.	B-O
In	B-O
addition,	B-O
RT-PCR	B-AC
data	B-O
showed	B-O
that	B-O
lovastatin	B-O
treatment	B-O
and	B-O
HMGCR	B-AC
knockdown	B-O
increased	B-O
the	B-O
mRNA	B-O
levels	B-O
of	B-O
HSP90	B-AC
in	B-O
ACHN	B-O
cells	B-O
.	B-O
Following	B-O
the	B-O
supplementation	B-O
of	B-O
various	B-O
metabolites	B-O
downstream	B-O
of	B-O
HMGCR,	B-O
the	B-O
rise	B-O
in	B-O
HSP90	B-AC
protein	B-O
concentration	B-O
appeared	B-O
to	B-O
be	B-O
attenuated	B-O
to	B-O
varying	B-O
degrees	B-O
.	B-O
Furthermore,	B-O
we	B-O
found	B-O
that	B-O
the	B-O
inhibition	B-O
of	B-O
HMGCR	B-AC
led	B-O
to	B-O
an	B-O
increase	B-O
in	B-O
the	B-O
level	B-O
of	B-O
heat	B-LF
shock	I-LF
transcription	I-LF
factor-1	I-LF
.	B-O
Collectively,	B-O
these	B-O
data	B-O
indicate	B-O
that	B-O
HSP90	B-AC
plays	B-O
a	B-O
critical	B-O
role	B-O
in	B-O
the	B-O
regulation	B-O
of	B-O
PKM2	B-AC
in	B-O
cells	B-O
when	B-O
inhibited	B-O
by	B-O
HMGCR.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
4.	B-O
HMGCR	B-AC
inhibition	B-O
increased	B-O
PKM2	B-AC
protein	B-O
level	B-O
by	B-O
up-regulating	B-O
HSP90	B-AC
expression.	B-O
.	B-O
Then,	B-O
we	B-O
investigated	B-O
whether	B-O
the	B-O
interaction	B-O
between	B-O
PKM2	B-AC
and	B-O
HSP90	B-AC
would	B-O
affect	B-O
the	B-O
abundance	B-O
of	B-O
PKM2	B-AC
in	B-O
ACHN	B-O
cells.	B-O
HSP90	B-AC
sh	B-O
RNA	I-LF
was	B-O
transfected	B-O
into	B-O
ACHN	B-O
cells	B-O
and	B-O
led	B-O
to	B-O
a	B-O
reduction	B-O
in	B-O
PKM2	B-AC
protein	B-O
level	B-O
with	B-O
reduced	B-O
HSP90	B-AC
expression	B-O
.	B-O
In	B-O
contrast,	B-O
the	B-O
exogenous	B-O
expression	B-O
of	B-O
HSP90	B-AC
significantly	B-O
increased	B-O
the	B-O
abundance	B-O
of	B-O
PKM2	B-AC
in	B-O
ACHN	B-O
cells	B-O
.	B-O
Next,	B-O
we	B-O
induced	B-O
protein	B-O
degradation	B-O
in	B-O
ACHN	B-O
cells	B-O
via	B-O
CHX	B-AC
and	B-O
found	B-O
that	B-O
the	B-O
half-life	B-O
of	B-O
PKM2	B-AC
changed	B-O
when	B-O
HSP90	B-AC
was	B-O
either	B-O
knocked	B-O
out	B-O
or	B-O
overexpressed	B-O
.	B-O
Simultaneously,	B-O
MG132	B-O
restored	B-O
the	B-O
protein	B-O
levels	B-O
of	B-O
PKM2	B-AC
that	B-O
had	B-O
been	B-O
reduced	B-O
in	B-O
response	B-O
to	B-O
HSP90	B-AC
knockdown	B-O
.	B-O
Furthermore,	B-O
we	B-O
performed	B-O
the	B-O
ubiquitination	B-O
assay	B-O
for	B-O
wild-type	B-O
PKM2.	B-O
Consistent	B-O
with	B-O
its	B-O
degradation	B-O
by	B-O
the	B-O
proteasomal	B-O
pathway,	B-O
PKM2	B-AC
was	B-O
extensively	B-O
ubiquitinated	B-O
in	B-O
ACHN	B-O
cells	B-O
in	B-O
which	B-O
HSP90	B-AC
had	B-O
been	B-O
knocked	B-O
down	B-O
.	B-O
Collectively,	B-O
these	B-O
data	B-O
indicated	B-O
that	B-O
HSP90	B-AC
was	B-O
critical	B-O
for	B-O
reducing	B-O
the	B-O
degradation	B-O
and	B-O
maintaining	B-O
the	B-O
stability	B-O
of	B-O
PKM2.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
5.	B-O
HSP90	B-AC
promoted	B-O
the	B-O
PKM2	B-AC
protein	B-O
stability	B-O
in	B-O
ACHN	B-O
cells.	B-O
.	B-O
Notably,	B-O
the	B-O
PKM2	B-AC
inhibitor	B-O
had	B-O
a	B-O
better	B-O
antitumor	B-O
effect	B-O
in	B-O
the	B-O
HMGCR	B-AC
inhibition	B-O
model	B-O
than	B-O
in	B-O
the	B-O
wild	B-O
type	B-O
model	B-O
.	B-O
The	B-O
changes	B-O
in	B-O
tumor	B-O
growth	B-O
were	B-O
consistent	B-O
with	B-O
lactate	B-O
levels	B-O
in	B-O
the	B-O
tumor	B-O
tissue,	B-O
the	B-O
release	B-O
of	B-O
VEGF	B-AC
and	B-O
GSH,	B-O
and	B-O
the	B-O
restoration	B-O
of	B-O
angiogenesis	B-O
.	B-O
In	B-O
vitro	B-O
assays,	B-O
culture	B-O
medium	B-O
testing,	B-O
and	B-O
cell	I-LF
ECAR	B-AC
monitoring	B-O
results	B-O
all	B-O
showed	B-O
that	B-O
the	B-O
supplementation	B-O
of	B-O
Shikonin	B-O
eliminated	B-O
the	B-O
increased	B-O
lactate	B-O
production	B-O
and	B-O
glucose	B-O
consumption	B-O
by	B-O
lovastatin,	B-O
to	B-O
a	B-O
level	B-O
that	B-O
was	B-O
even	B-O
lower	B-O
than	B-O
the	B-O
control;	B-O
these	B-O
findings	B-O
were	B-O
consistent	B-O
with	B-O
the	B-O
potent	B-O
ability	B-O
of	B-O
Shikonin	B-O
to	B-O
inhibit	B-O
glycolysis	B-O
.	B-O
These	B-O
results	B-O
proved	B-O
that	B-O
the	B-O
suppression	B-O
of	B-O
glycolysis	B-O
reversed	B-O
the	B-O
acceleration	B-O
of	B-O
tumor	B-O
growth	B-O
caused	B-O
by	B-O
HMGCR	B-AC
inhibition	B-O
and	B-O
provided	B-O
antitumor	B-O
effects	B-O
in	B-O
mice.	B-O
Download:	B-O
PPT	B-O
PowerPoint	B-O
slide	B-O
PNG	B-O
larger	B-O
image	B-O
TIFF	B-O
original	B-O
image	B-O
Fig	B-O
6.	B-O
Glycolysis	B-O
suppression	B-O
reverses	B-O
HMGCR	B-AC
inhibition	B-O
induced	B-O
tumor	B-O
growth	B-O
in	B-O
xenograft	B-O
mice.	B-O
.	B-O
Recent	B-O
studies	B-O
indicated	B-O
that	B-O
the	B-O
use	B-O
of	B-O
statins	B-O
significantly	B-O
increased	B-O
the	B-O
expression	B-O
of	B-O
Hsp90,	B-O
while	B-O
in	B-O
vitro	B-O
studies	B-O
demonstrated	B-O
that	B-O
the	B-O
statin-induced	B-O
activation	B-O
of	B-O
HSP90	B-AC
was	B-O
associated	B-O
with	B-O
the	B-O
phosphorylation	B-O
of	B-O
endothelial	B-LF
NO	I-LF
synthase	I-LF
.	B-O
A	I-LF
previous	B-O
study	B-O
showed	B-O
that	B-O
the	B-O
administration	B-O
of	B-O
atorvastatin	B-O
in	B-O
the	B-O
human	B-O
coronary	B-O
artery	B-O
endothelial	B-LF
cell	I-LF
model	B-O
up-regulated	B-O
the	B-O
levels	B-O
of	B-O
HSF-1	B-AC
protein	B-O
.	B-O
HSF-1	B-AC
might	B-O
be	B-O
a	B-O
key	B-O
enzyme	B-O
involved	B-O
in	B-O
the	B-O
mechanism	B-O
by	B-O
which	B-O
HMGCR	B-AC
regulates	B-O
HSP90.	B-O
However,	B-O
the	B-O
precise	B-O
identification	B-O
of	B-O
the	B-O
mechanisms	B-O
by	B-O
which	B-O
HMGCR	B-AC
regulates	B-O
HSP90	B-AC
has	B-O
yet	B-O
to	B-O
be	B-O
identified.	B-O
The	B-O
Warburg	B-O
effect	B-O
shows	B-O
that	B-O
despite	B-O
having	B-O
enough	B-O
oxygen,	B-O
tumor	B-O
cells	B-O
still	B-O
enhance	B-O
their	B-O
glycolysis	B-O
pathways	B-O
and	B-O
use	B-O
more	B-O
glucose	B-O
to	B-O
synthesize	B-O
glycolysis	B-O
intermediates	B-O
to	B-O
maintain	B-O
their	B-O
cell	I-LF
growth,	B-O
division,	B-O
and	B-O
survival	B-O
.	B-O
In	B-O
this	B-O
study,	B-O
we	B-O
found	B-O
that	B-O
HMGCR	B-AC
inhibition	B-O
did	B-O
not	B-O
directly	B-O
promote	B-O
the	B-O
proliferation	B-O
of	B-O
cells	B-O
but	B-O
increased	B-O
the	B-O
rate	I-LF
of	B-O
glycolysis	B-O
and	B-O
enhance	B-O
the	B-O
Warburg	B-O
effect	B-O
of	B-O
cells.	B-O
Moreover,	B-O
the	B-O
reprogramming	B-O
of	B-O
cellular	B-O
metabolism	B-O
provides	B-O
a	B-O
microenvironment	B-O
that	B-O
is	B-O
suitable	B-O
for	B-O
the	B-O
accelerated	B-O
growth	B-O
of	B-O
tumors.	B-O
Aerobic	B-O
glycolysis	B-O
by	B-O
a	B-O
tumor	B-O
has	B-O
a	B-O
significant	B-O
interaction	B-O
with	B-O
effect	B-O
on	B-O
the	B-O
TME	B-AC
.	B-O
Enhanced	B-O
glycolysis	B-O
and	B-O
elevated	B-O
levels	B-O
of	B-O
lactate	B-O
lead	B-O
to	B-O
the	B-O
acidification	I-LF
of	B-O
the	B-O
TME,	B-O
thus	B-O
activating	B-O
a	B-O
variety	B-O
of	B-O
low	B-O
pH-dependent	B-O
genes	B-O
that	B-O
are	B-O
related	B-O
to	B-O
tumor	B-O
invasion	B-O
and	B-O
metastasis	B-O
[	B-O
49	B-O
,	B-O
50	B-O
].	B-O
TME	B-AC
is	B-O
the	B-O
key	B-O
regulator	B-O
of	B-O
carcinogenesis	B-O
and	B-O
is	B-O
composed	B-O
of	B-O
many	B-O
different	B-O
types	B-O
of	B-O
cells,	B-O
including	B-O
duo-malignant	B-O
cancer	B-O
cells,	B-O
cancer-associated	B-LF
fibroblasts	B-O
Dose-dependent	B-O
lovastatin	B-O
treated	B-O
on	B-O
the	B-O
proliferation	B-O
of	B-O
ACHN	B-O
and	B-O
786-O	B-O
cells.	B-O
The	B-O
effect	B-O
of	B-O
lovastatin	B-O
or	B-O
sh	B-O
HMGCR	B-AC
intervention	B-O
on	B-O
the	B-O
protein	B-O
levels	B-O
of	B-O
glycolysis-related	B-O
enzymes.	B-O
or	B-O
HMGCR	B-AC
knockdown	B-O
Western	B-O
blotting	B-O
analysis	B-O
of	B-O
HSP90	B-AC
after	B-O
lentiviral	B-O
knockdown	B-O
as	B-O
exemplified	B-O
in	B-O
ACHN	B-O
cells.	B-O
Immunohistochemical	B-O
staining	B-O
of	B-O
CD31+	B-O
in	B-O
ACHN	B-O
cell	I-LF
xenografts	B-O
(scale	B-O
bar:	B-O
50	B-O
μm).	B-O
(B)	B-O
Extracellular	B-O
lactate	B-O
level,	B-O
(C)	B-O
glucose	B-O
consumption,	B-O
and	B-O
(D)	B-O
ECAR	B-AC
rate	I-LF
of	B-O
ACHN	B-O
cell	I-LF
with	B-O
or	B-O
without	B-O
lovastatin	B-O
and	B-O
Shikonin	B-O
treatment.	B-O
The	B-O
data	B-O
are	B-O
represented	B-O
as	B-O
the	B-O
mean	B-O
±	B-O
SD	B-AC
from	B-O
3	B-O
independent	B-O
experiments,	B-O
*(	B-O
p	B-O
≤	B-O
0.05),	B-O
**(	B-O
p	B-O
≤	B-O
0.01)	B-O
or	B-O
***	B-O
p	B-O
≤	B-O
0.001).	B-O
2DG,	B-O
2-deoxy-D-glucose;	B-O
ECAR,	B-O
extracellular	B-LF
acidification	I-LF
rate;	B-O
Glu,	B-O
glucose;	B-O
HMGCR,	B-O
3-hydroxy-3-methylglutaryl	B-LF
coenzyme	I-LF
A	I-LF
reductase;	B-O
Lov,	B-O
lovastatin;	B-O
Oligo,	B-O
oligomycin;	B-O
PKM2,	B-O
pyruvate	B-LF
kinase	I-LF
M2;	B-O
RCC,	B-O
renal	B-LF
cell	I-LF
carcinoma;	B-O
SK,	B-O
Shikonin;	B-O
wt	B-O
,	B-O
wild	B-O
type.	B-O
(TIF)	B-O
S1	B-O
Raw	B-O
Images.	B-O
(PDF)	B-O
